Who will Theralase partner with?Roger Dumoulin-White quote from yesterday's video.
"I think that we take a page book out of the pharma companies. And what they do is, they tend to partner. So they have their drug, they tend to partner with other pharmaceutical companies and say "Hey, let's do a combinational study. We have our drug you have your drug. Let's put them together and see if we get a synergistic effect." We would take that same playbook. So we have our drug - we develop it. So our next step is really what's called a GLP toxicology study, which allows us to do testing to set the human equivalent dose etc...what's safe in patients and what's effective etc."
"So we plan to do that in fourth quarter, subject, of course, to having the funds to cover that. With that information though, it would provide us with an ability to inject our drug into human patients in a phase 1 clinical study. From there it becomes exciting because other pharmaceutical companies, knowing the data that we produced on this pre-clinical model would say, "Well, how about we combine it with our drug and see what happens for this condition, or we combine it with this other drug and see what happens?" So it opens up a whole bunch of partnering opportunities, which I think would be very important for the company." Theralase Explores Synergistic Drug Combinations for Cancer Treatment